{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["14(11)"],"submitter":["Manuel Sousa J"],"funding":["AbbVie"],"pubmed_abstract":["<h4>Aim</h4>We describe the effectiveness and safety of the interferon-free regimen ombitasvir/paritaprevir/ritonavir plus dasabuvir with or without ribavirin (OBV/PTV/r ± DSV ± RBV) in a nationwide representative sample of the hepatitis C virus (HCV) monoinfected and human immunodeficiency virus-1/hepatitis C virus (HIV/HCV) coinfected population in Spain.<h4>Material and methods</h4>Data were collected from patients infected with HCV genotypes 1 or 4, with or without HIV-1 coinfection, treated with OBV/PTV/r ± DSV ± RBV at 61 Spanish sites within the initial implementation year of the first government-driven \"National HCV plan.\" Effectiveness was assessed by sustained virologic response at post-treatment week 12 (SVR12) and compared between monoinfected and coinfected patients using a no"],"journal":["PloS one"],"pagination":["e0225061"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6850697"],"repository":["biostudies-literature"],"pubmed_title":["Real-world evidence of the effectiveness of ombitasvir-paritaprevir/r ± dasabuvir ± ribavirin in patients monoinfected with chronic hepatitis C or coinfected with human immunodeficiency virus-1 in Spain."],"pmcid":["PMC6850697"],"pubmed_authors":["Rodriguez M","Espinosa N","Magaz M","Mateos-Munoz B","Sanchez Antolin G","Pulido F","Gallego A","Aguilar P","Carnicer F","Moreno-Planas JM","Vergara M","Manzanares A","Delgado M","Rico M","Menendez F","Moran-Sanchez S","Hernandez-Guerra M","Jou A","Rubin A","Manuel Sousa J","Zozaya JM","Garcia-Buey L","Aldamiz-Echevarria T","Carrion JA","Rincon D","Chimeno-Hernandez S","Polo-Lorduy B","Estebanez A","Sampedro B","Lorente S","Izquierdo S","Andrade RJ","Von-Wichmann MA","Hijona L","Salmeron J","Escarda A","Morillas RM","Martin-Granizo I","Morano L"],"additional_accession":[]},"is_claimable":false,"name":"Real-world evidence of the effectiveness of ombitasvir-paritaprevir/r ± dasabuvir ± ribavirin in patients monoinfected with chronic hepatitis C or coinfected with human immunodeficiency virus-1 in Spain.","description":"<h4>Aim</h4>We describe the effectiveness and safety of the interferon-free regimen ombitasvir/paritaprevir/ritonavir plus dasabuvir with or without ribavirin (OBV/PTV/r ± DSV ± RBV) in a nationwide representative sample of the hepatitis C virus (HCV) monoinfected and human immunodeficiency virus-1/hepatitis C virus (HIV/HCV) coinfected population in Spain.<h4>Material and methods</h4>Data were collected from patients infected with HCV genotypes 1 or 4, with or without HIV-1 coinfection, treated with OBV/PTV/r ± DSV ± RBV at 61 Spanish sites within the initial implementation year of the first government-driven \"National HCV plan.\" Effectiveness was assessed by sustained virologic response at post-treatment week 12 (SVR12) and compared between monoinfected and coinfected patients using a no","dates":{"release":"2019-01-01T00:00:00Z","publication":"2019","modification":"2026-04-29T11:32:12.632Z","creation":"2020-05-21T19:56:48Z"},"accession":"S-EPMC6850697","cross_references":{"pubmed":["31714950"],"doi":["10.1371/journal.pone.0225061"]}}